Cash grants

Between cycles

Funds a UK technology SME and its industry partner adopting digital twin technology through an Innovate UK grant delivered by Digital Catapult.

Between cycles

Funds Chilean neighborhood retail stores adopting digital management tools and upgrading commercial operations.

Between cycles

Funds Duke faculty, staff, students and trainees $25,000 to $60,000 a year to pilot practical healthcare innovation projects inside Duke's clinical enterprise.

Between cycles

Supports United Kingdom cancer science programmes with multi-stage funding for innovation in disease biology.

Between cycles

Funds disease-model development programs for IRD and AMD translational research.

Between cycles

Funds research teams and institutions for DOE Early Career Research in energy systems, artificial intelligence, and quantum systems.

Between cycles

Backs research teams and institutions for DOE Energy Frontier Research Centers in energy systems, materials science, and quantum systems.

Between cycles

Invests in teams advancing energy, climate, and manufacturing innovation projects.

Between cycles

Supports agricultural and natural resource science in the Philippines through competitive grant calls for universities and research institutions.

Between cycles

Funds clinical research or trials that improve dementia care itself, not drug treatments alone, for people with Alzheimer's and their care partners.

Between cycles

Funds non-drug research that removes a barrier to diagnosing, monitoring or accurately predicting the course of Alzheimer's disease and related dementias.

Between cycles

Funds research into Alzheimer's risk factors or prevention strategies, aimed at stopping the disease before it starts rather than treating it after.

Between cycles

Funds developing or validating the biomarkers and outcome measures that make ALS clinical trials sharper, not the trials themselves.

Between cycles

Funds a phase 1 or small phase 2 ALS clinical trial that must start within a year of the award, with a biomarker built in for any drug, biologic or device.

Between cycles

Funds preclinical-to-IND-enabling work on an ALS drug that already has proof-of-concept efficacy data and a lead compound in hand.

Between cycles

Funds an early, hypothesis-driven ALS drug or therapy idea before there's data proving it will work.

Between cycles

Funds a human study of arthritis at whichever of two scales the evidence supports — a pilot or a full trial.

Between cycles

Funds preclinical or animal arthritis research that's too applied to count as basic science and not yet ready for people.

Between cycles

Funds a clinical trial of a new autism treatment, product or device, from a small proof-of-concept study up to a full efficacy trial.

Between cycles

Funds an innovative, high-risk autism research idea aimed at a critical problem or need, before there's a trial to run.

Between cycles

Funds breast cancer research mature enough to run a small clinical trial, though a trial is not required at this level.

Between cycles

Funds preclinical or clinical Duchenne muscular dystrophy research, at a smaller or a larger funding level.

Between cycles

Funds an early-stage idea in Duchenne muscular dystrophy research, without requiring a clinical trial.

Between cycles

Funds drug discovery and therapy development for hearing loss from military-relevant injury, not tinnitus or balance disorders.